EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Extracellular vesicles in cardiovascular disease: Biomarkers, therapeutic applications, and drug delivery strategies

Qamar Abuhassan, Amirali Salajegheh, Faris Anad Muhammad, Ali Fawzi Al-Hussainy, Tushar B Gajjar, Malathi Hanumanthayya, Sandeep Kumar Shukla, Rajashree Panigrahi, Neeraj Bainsal, Djamila Polatova, Hayder Naji Sameer, Rasim M Salih und 1 weitere

Clinica Chimica Acta · 2026-06 · 588 · 120972

DOI: 10.1016/j.cca.2026.120972 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinica Chimica Acta, 2026-06. Verfasst von Qamar Abuhassan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Pharmaceutical Technology, School of Pharmacy, University of Jordan, Amman 11942, Jordan. Hauptthemen laut MEDLINE: Extracellular Vesicles, Cardiovascular Diseases, Drug Delivery Systems. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 101 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extracellular vesicles (EVs) have emerged as pivotal mediators of intercellular communication in cardiovascular disease (CVD), influencing inflammation, thrombosis, fibrosis, angiogenesis, and cardiac remodeling through the transfer of proteins, lipids, and RNAs. The presence of EVs in virtually all biofluids and their cargo's close linkage to cellular activation or injury make EVs attractive noninvasive biomarkers for CVD diagnosis, prognosis, and therapy monitoring, with circulating EV signatures reported in myocardial infarction, heart failure, atherosclerosis, and valvular and cardiomyopathic disorders. Parallel advances highlight EVs as cell-free therapeutic agents, recapitulating key paracrine benefits of stem and progenitor cell therapies while avoiding issues of low engraftment and arrhythmogenic risk. In addition to their endogenous activity, both native and engineered EVs are being actively developed as drug delivery platforms, offering biocompatibility, immune stealth, and the capacity to cross biological barriers, with promising data for targeted delivery to the ischemic myocardium and atherosclerotic plaques. Engineering strategies, including surface functionalization, controlled cargo loading, and combination with biomaterials such as hydrogels, can increase cardiac homing, prolong circulation, and improve on-target efficacy. Despite this promise, major hurdles remain: heterogeneity of EV subtypes, lack of standardized isolation and characterization workflows, low production yields, incomplete pharmacokinetic understanding, and unresolved regulatory classification. Addressing these limitations through multi-omics, advanced bioengineering, scalable bioprocessing, and rigorously designed clinical trials will be critical to integrate EV-based biomarkers, therapeutics, and delivery systems into cardiovascular precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesCardiovascular DiseasesDrug Delivery SystemsHumansBiomarkersAnimals

Stichwörter der Autor:innen

BiomarkersCardiovascular diseaseCell-free therapyDrug deliveryExtracellular vesicles

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Pharmaceutics and Pharmaceutical Technology, School of Pharmacy, University of Jordan, Amman 11942, Jordan.
  • Department of Pharmaceutical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
  • College of Pharmacy, Alnoor University, Nineveh, Iraq. Electronic address: faris.anad@alnoor.edu.iq.
  • College of Pharmacy, Ahl Al Bayt University, Kerbala, Iraq.
  • Department of Pharmacy, Faculty of Pharmacy, Gokul Global University, Sidhpur, Gujarat, India.
  • Department of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.

Zitieren

APA

Abuhassan, Q., Salajegheh, A., Muhammad, F. A., Al-Hussainy, A. F., Gajjar, T. B., Hanumanthayya, M., Shukla, S. K., Panigrahi, R., Bainsal, N., Polatova, D., Sameer, H. N., Salih, R. M., & Adil, M. (2026). Extracellular vesicles in cardiovascular disease: Biomarkers, therapeutic applications, and drug delivery strategies. Clinica Chimica Acta, 588, 120972. https://doi.org/10.1016/j.cca.2026.120972

Vancouver

Abuhassan Q, Salajegheh A, Muhammad FA, Al-Hussainy AF, Gajjar TB, Hanumanthayya M, et al. Extracellular vesicles in cardiovascular disease: Biomarkers, therapeutic applications, and drug delivery strategies. Clinica Chimica Acta. 2026;588:120972. doi:10.1016/j.cca.2026.120972

BibTeX
@article{Abuhassan2026,
  author = {Abuhassan, Qamar and Salajegheh, Amirali and Muhammad, Faris Anad and Al-Hussainy, Ali Fawzi and Gajjar, Tushar B and Hanumanthayya, Malathi and Shukla, Sandeep Kumar and Panigrahi, Rajashree and Bainsal, Neeraj and Polatova, Djamila and Sameer, Hayder Naji and Salih, Rasim M and Adil, Mohaned},
  title = {Extracellular vesicles in cardiovascular disease: Biomarkers, therapeutic applications, and drug delivery strategies},
  journal = {Clinica Chimica Acta},
  year = {2026},
  volume = {588},
  pages = {120972},
  doi = {10.1016/j.cca.2026.120972}
}
Kostenlos starten →